Back to Search
Start Over
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
- Source :
-
International journal of cancer [Int J Cancer] 2011 Dec 15; Vol. 129 (12), pp. 2836-46. Date of Electronic Publication: 2011 Mar 29. - Publication Year :
- 2011
-
Abstract
- We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 μg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.<br /> (Copyright © 2011 UICC.)
- Subjects :
- Adult
Aged
Antigens biosynthesis
CD4-Positive T-Lymphocytes immunology
CD8-Positive T-Lymphocytes immunology
Cancer Vaccines adverse effects
Cancer Vaccines immunology
Female
Humans
Immunity, Humoral
Male
Mannitol immunology
Middle Aged
Neoplasms immunology
Picibanil immunology
Treatment Outcome
Antigens, Neoplasm immunology
Cancer Vaccines therapeutic use
Mannitol analogs & derivatives
Membrane Proteins immunology
Neoplasms therapy
Oleic Acids immunology
Peptide Fragments immunology
Vaccines, Subunit therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0215
- Volume :
- 129
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- International journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 21448901
- Full Text :
- https://doi.org/10.1002/ijc.25955